(XNCR) Xencor - Ratings and Ratios

Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company specializing in the development of engineered monoclonal antibodies for the treatment of immune-related diseases and cancer. Leveraging its proprietary XmAb Fc technology, the company enhances antibody performance by improving immune cell engagement and extending half-life. Its approved products include Ultomiris for atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder; Monjuvi for relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab, targeting SARS-CoV-2. Xencors pipeline encompasses multiple investigational candidates, including XmAb819 for renal cell carcinoma, XmAb541 in Phase I for ovarian cancer, and XmAb808, a bispecific antibody targeting a broadly expressed tumor antigen.

The companys pipeline continues with Vudalimab in Phase II for metastatic castration-resistant prostate cancer, XmAb564 for autoimmune diseases, XmAb662 in Phase I for solid tumors, XmAb942 in Phase I for Crohns disease and ulcerative colitis, and Plamotamab in Phase I for lymphoma. Additional candidates include Xaluritamig, a bispecific T-cell engager for prostate cancer; Obexelimab for immunoglobulin G4-related disease; Teropavimab and Zinlirvimab for HIV; Tobevibart for hepatitis Delta virus; Novartis, utilizing XmAb Fc technology; Xpro1595 for Alzheimers disease and treatment-resistant depression; Zaltenibart for paroxysmal nocturnal hemoglobinuria; ASP2138 for gastric and pancreatic cancers; JNJ-9401 for prostate cancer; and JNJ-1493 for B-cell malignancies. Incorporated in 1997, Xencor is headquartered in Pasadena, California.

Forecast: Based on technical indicators, Xencors stock (XNCR) shows a last price of $8.46, below its 20-day SMA of $9.88, 50-day SMA of $11.46, and 200-day SMA of $18.29, indicating potential selling pressure. The average volume of 913,350 shares suggests moderate liquidity. With a market cap of $762.75M and P/S ratio of 6.90, the company is valued at a premium, reflecting its clinical-stage pipeline. The negative RoE of -36.09% highlights ongoing R&D investments. While the stock may face near-term volatility due to its distance below key moving averages, the companys diverse pipeline and technological advancements position it for potential long-term growth in the biopharmaceutical sector.